Cel-Sci continues to tout the potential of its immunotherapy, but the company is running out of time and investor patience.
Last-ditch attempts by CEL-SCI to persuade investors that its cancer drug candidate Multikine has a future have fallen flat and the company may be facing bankruptcy and the end of its chequered history.
Cel-Sci has been around since 1983 without ever having brought a product to market, but has sustained itself on hopes...
The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.
Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.
BlissBio is to single-handedly move BB-1701, its eribulin-containing, HER2-targeting antibody-drug conjugate, into a global pivotal Phase II/III program for HER2-expressing, Enhertu-resistant breast cancer.
